Compare SUNS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | DTIL |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 128.8M |
| IPO Year | N/A | 2019 |
| Metric | SUNS | DTIL |
|---|---|---|
| Price | $7.99 | $6.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.75 | ★ $60.00 |
| AVG Volume (30 Days) | 91.1K | ★ 317.3K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 14.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $91.00 | N/A |
| Revenue Next Year | $20.79 | $34.75 |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $3.53 |
| 52 Week High | $11.78 | $8.82 |
| Indicator | SUNS | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 28.53 | 59.75 |
| Support Level | N/A | $3.96 |
| Resistance Level | $9.69 | $7.59 |
| Average True Range (ATR) | 0.27 | 0.58 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 4.58 | 44.61 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.